Modified polymerases for improved incorporation of nucleotide analogues

Patent metadata

Field	Value
Publication number	US-12110514-B2
Application number	US-202016953882-A
Country	US
Kind code	B2
Filing date	Nov 20, 2020
Priority date	Jun 27, 2014
Publication date	Oct 8, 2024
Grant date	Oct 8, 2024

Abstract

Presented herein are polymerase enzymes for improved incorporation of nucleotide analogues, in particular nucleotides which are modified at the 3′ sugar hydroxyl, as well as methods and kits using the same.

First claim

What is claimed is:

1. An altered family B archaeal polymerase comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:10, wherein the altered polymerase comprises amino acid substitution mutations at the positions functionally equivalent to Lys477 and Ala485 in the wild-type 9°N DNA polymerase amino acid sequence of SEQ ID NO:5.

2. The altered polymerase of claim 1 , wherein the altered polymerase comprises a substitution mutation functionally equivalent to Lys477Met in the 9°N polymerase amino acid sequence.

3. The altered polymerase of claim 1 , wherein the altered polymerase comprises a substitution mutation functionally equivalent to Ala485Leu or Ala485Val in the 9°N polymerase amino acid sequence.

4. The altered polymerase of claim 1 , wherein the altered polymerase further comprises substitution mutations at one or more positions functionally equivalent to Asp141 and/or Glu143 in the 9°N DNA polymerase amino acid sequence.

5. The altered polymerase of claim 1 , further comprising a substitution mutation at the position functionally equivalent to Cys223 in the 9°N DNA polymerase amino acid sequence.

6. The altered polymerase of claim 5 , wherein the altered polymerase comprises a substitution mutation functionally equivalent to Cys223Ser in the 9°N polymerase amino acid sequence.

7. The altered polymerase of claim 1 , further comprising a substitution mutation at the position functionally equivalent to Thr514 in the 9°N DNA polymerase amino acid sequence.

8. The altered polymerase of claim 7 , wherein the altered polymerase comprises a substitution mutation functionally equivalent to Thr514Ala or Thr514Ser in the 9°N polymerase amino acid sequence.

9. The altered polymerase of claim 1 , further comprising a substitution mutation at the position functionally equivalent to Ile521 in the 9°N DNA polymerase amino acid sequence.

10. The altered polymerase of claim 9 , wherein the altered polymerase comprises a substitution mutation functionally equivalent to Ile521Leu in the 9°N polymerase amino acid sequence.

11. The altered polymerase of claim 1 , further comprising substitution mutations at the positions functionally equivalent to Leu408, Tyr409, and Pro410 in the 9°N DNA polymerase amino acid sequence.

12. The altered polymerase of claim 11 , wherein the altered polymerase comprises substitution mutations functionally equivalent to Leu408Ala, Tyr409Ala, and Pro410Ile in the 9°N polymerase amino acid sequence.

13. The altered polymerase of claim 1 , wherein the altered polymerase comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 10.

14. A recombinant DNA polymerase comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 29 and comprises Val485, which recombinant DNA polymerase comprises an amino acid substitution mutation homologous to Lys477Met in the 9°N DNA polymerase amino acid sequence of SEQ ID NO:29.

15. A recombinant DNA polymerase comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 31 and comprises Val485, which recombinant DNA polymerase comprises an amino acid substitution mutation to Lys477Met in the 9°N DNA polymerase amino acid sequence of SEQ ID NO:31.

Assignees

• Illumina Inc

Inventors

• Chen Cheng-Yao
• Bomati Erin
• He Molly

Classifications

• C12Y207/07007

  DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

• C12N9/1252 Primary

  DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title